A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Date publication

avril 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian

Tous les auteurs :
Galot R, Le Tourneau C, Licitra L, Guigay J, Kong A, Tinhofer I, Even C, Daste A, Henry S, Borel C, Abdeddaim C, Seront E, Prevost JB, Rutten A, Saada-Bouzid E, Rolland F, Bonomo P, Rasschaert M, Dirix L, Olungu C, Tsechilidou K, Govaerts AS, Fortpied C, Joaquim A, Machiels JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40311183

Résumé

Monalizumab (M), targeting the natural killer group 2A (NKG2A) receptor, has limited activity as monotherapy in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Preliminary data of M and durvalumab (D) have shown encouraging activity in other tumor types.

Mots clés

I2, UPSTREAM, immunotherapy, monalizumab, squamous cell carcinoma of the head and neck

Référence

ESMO Open. 2025 04 30;10(5):104554